Our study preliminarily showed manageable toxicity and clinical benefit of inetetamab plus pyrotinib in HER2‐mutant patients with advanced NSCLC, providing a promising combination therapy deserving further study. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.